Josh Mailman, MBA, the president of NorCal CarciNET, discusses the management of neuroendocrine tumors (NETs) through a patient’s perspective. He reports on overall patients’ attitudes toward Gallium Ga 68-DOTATATE imaging and the newly-approved Lutetium Lu 177 Dotatate therapy, as well as advocacy in the NETs patient community.Read More
Josh Mailman, MBA
NorCal CariciNET Community
Josh is an internationally-recognized advocate for Neuroendocrine tumor patients as well as an advocate for integrative oncology and nuclear medicine and molecular imaging. He is the inaugural chairman of the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) Patient Advocacy Advisory Board, a member of The Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF) Board and president of NorCal CarciNET Community, one of the largest NET patient groups in the United States. In addition, he has been a member of the National Cancer Institute’s Task Force on Neuroendocrine Tumors for over 3 years.